search
Back to results

Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients With Rhabdomyolysis

Primary Purpose

Rhabdomyolysis

Status
Withdrawn
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
CytoSorb Device
CVVH
Sponsored by
CytoSorbents, Inc
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Rhabdomyolysis

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subject is age 18-80
  • Subjects present with rhabdomyolysis
  • Subject requires renal replacement therapy and has undergone adequate volume resuscitation
  • Subject is willing to comply with specified follow up requirements

Exclusion Criteria:

  • Subject or their legal guardian either declines or cannot give informed consent
  • Subject is pregnant
  • Subject has been previously enrolled in this clinical study
  • Comorbid condition that may limit survival to ≤14 days
  • Comorbid condition that could confound study results
  • Subjects who are receiving immunosuppressive therapy

Sites / Locations

  • San Antonio Military Medical Center- US Army Institute of Surgical Research- Burn Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

CVVH

CytoSorb Device

Arm Description

Outcomes

Primary Outcome Measures

Efficacy of device as measured by change in myoglobin
Assessment of serious device or procedure-related adverse events

Secondary Outcome Measures

Full Information

First Posted
March 19, 2014
Last Updated
April 6, 2023
Sponsor
CytoSorbents, Inc
Collaborators
San Antonio Military Medical Center (SAMMC), US Army Institute of Surgical Research-Burn Center
search

1. Study Identification

Unique Protocol Identification Number
NCT02111018
Brief Title
Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients With Rhabdomyolysis
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Withdrawn
Why Stopped
Lack of enrollment
Study Start Date
March 2014 (undefined)
Primary Completion Date
June 2016 (Anticipated)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
CytoSorbents, Inc
Collaborators
San Antonio Military Medical Center (SAMMC), US Army Institute of Surgical Research-Burn Center

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Prospective, randomized non-blinded, controlled study to assess the feasibility of the CytoSorb as an adjunct to the standard of care in patients with rhabdomyolysis requiring renal replacement therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rhabdomyolysis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CVVH
Arm Type
Active Comparator
Arm Title
CytoSorb Device
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
CytoSorb Device
Intervention Type
Procedure
Intervention Name(s)
CVVH
Primary Outcome Measure Information:
Title
Efficacy of device as measured by change in myoglobin
Time Frame
30 days
Title
Assessment of serious device or procedure-related adverse events
Time Frame
30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject is age 18-80 Subjects present with rhabdomyolysis Subject requires renal replacement therapy and has undergone adequate volume resuscitation Subject is willing to comply with specified follow up requirements Exclusion Criteria: Subject or their legal guardian either declines or cannot give informed consent Subject is pregnant Subject has been previously enrolled in this clinical study Comorbid condition that may limit survival to ≤14 days Comorbid condition that could confound study results Subjects who are receiving immunosuppressive therapy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
LTC Kevin Chung, MD
Organizational Affiliation
San Antonio Military Medical Center-US Army Institute of Surgical Research-Burn Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
MAJ Ian Stewart, MD
Organizational Affiliation
San Antonio Military Medical Center-US Army Institute of Surgical Research- Burn Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
San Antonio Military Medical Center- US Army Institute of Surgical Research- Burn Center
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78234
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients With Rhabdomyolysis

We'll reach out to this number within 24 hrs